Published in Am J Pathol on May 01, 1996
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34
The pathobiology of splicing. J Pathol (2010) 2.52
Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem (2012) 2.23
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther (2008) 1.95
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell (2012) 1.93
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 1.89
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis (2010) 1.87
Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol (2001) 1.59
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer (2010) 1.51
Histopathological evaluation of apoptosis in cancer. Am J Pathol (1998) 1.31
MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer (2010) 1.28
Spindle poisons and cell fate: a tale of two pathways. Mol Interv (2011) 1.24
Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One (2012) 1.23
Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther (2014) 1.23
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res (2007) 1.22
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res (2004) 1.19
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov (2015) 1.15
Expression and significance of proapoptotic gene Bax in gastric carcinoma. World J Gastroenterol (1999) 1.14
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer (2009) 1.12
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets (2010) 1.11
Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol (2003) 1.10
Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer (2006) 1.09
VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One (2012) 1.08
Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol (1996) 1.08
Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer (2004) 1.07
Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07
TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. Am J Pathol (1998) 1.07
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
Integrin signaling aberrations in prostate cancer. Am J Transl Res (2009) 1.01
Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res (2009) 1.01
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget (2010) 1.01
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer (1999) 1.01
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol (2014) 1.00
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol (1999) 0.99
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate (2010) 0.98
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct (2010) 0.97
CED-9 and mitochondrial homeostasis in C. elegans muscle. J Cell Sci (2008) 0.97
βArrestin-1 and Mcl-1 modulate self-renewal growth of cancer stem-like side-population cells in non-small cell lung cancer. PLoS One (2013) 0.96
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis (2009) 0.94
Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One (2012) 0.94
Squamous cell carcinoma antigen suppresses radiation-induced cell death. Br J Cancer (2001) 0.93
Subditine, a new monoterpenoid indole alkaloid from bark of Nauclea subdita (Korth.) Steud. induces apoptosis in human prostate cancer cells. PLoS One (2014) 0.93
Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. Am J Pathol (1999) 0.93
Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One (2009) 0.91
Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer (2003) 0.90
Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer (2000) 0.89
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl (2010) 0.89
Molecular and genetic prognostic factors of prostate cancer. World J Urol (2003) 0.89
Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Adv Cancer Res (2012) 0.88
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol (2013) 0.88
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol (2013) 0.87
Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic. Oncotarget (2015) 0.87
Modulation of 5' splice site selection using tailed oligonucleotides carrying splicing signals. BMC Biotechnol (2006) 0.87
Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. J Med Chem (2015) 0.87
Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol (2005) 0.87
The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer (2001) 0.86
Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer (2001) 0.86
BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One (2013) 0.86
Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol (2011) 0.86
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. PLoS One (2013) 0.85
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics (2008) 0.84
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med (2008) 0.84
Comparative Genomic Analysis of Classical and Variant Virulent Parental/Attenuated Strains of Porcine Epidemic Diarrhea Virus. Viruses (2015) 0.84
Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect (1999) 0.83
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget (2014) 0.82
Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101). BMC Cancer (2015) 0.82
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer (2013) 0.81
Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer (1998) 0.80
Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate. Am J Pathol (1997) 0.80
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Comparison of morphology and biocompatibility of acellular nerve scaffolds processed by different chemical methods. J Mater Sci Mater Med (2014) 0.80
Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer. Cancer Genomics Proteomics (2016) 0.79
BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer. Gastric Cancer (2015) 0.79
Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.79
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget (2015) 0.79
Molecular targets for radiation oncology in prostate cancer. Front Oncol (2011) 0.78
Caspase-3 feedback loop enhances Bid-induced AIF/endoG and Bak activation in Bax and p53-independent manner. Cell Death Dis (2015) 0.78
Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia. World J Gastroenterol (2003) 0.78
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma (2015) 0.78
An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. Transl Oncol (2014) 0.78
Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun (2017) 0.78
Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer (2000) 0.77
N52 monodeamidated Bcl‑xL shows impaired oncogenic properties in vivo and in vitro. Oncotarget (2016) 0.77
Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer (1998) 0.77
Precursor lesions for prostate cancer. J R Soc Med (1997) 0.77
4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in Rats. PLoS One (2016) 0.77
Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today (2011) 0.77
The predictive value of immunohistochemical markers in untreated Wilms' tumour: are they useful? World J Urol (2011) 0.76
Pigment epithelium derived factor inhibits the growth of human endometrial implants in nude mice and of ovarian endometriotic stromal cells in vitro. PLoS One (2012) 0.76
Synuclein-γ suppression mediated by RNA interference inhibits the clonogenicity and invasiveness of MCF-7 cells. Oncol Lett (2013) 0.76
Deletion of Na+/H+ exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24. Am J Physiol Gastrointest Liver Physiol (2016) 0.76
Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression. Int J Clin Exp Pathol (2015) 0.75
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell (1993) 20.72
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
Bcl-2 and the regulation of programmed cell death. J Cell Biol (1994) 7.88
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (1994) 6.69
Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res (1993) 5.83
Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A (1986) 5.54
Cancer statistics, 1995. CA Cancer J Clin (1995) 4.73
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res (1992) 4.00
Checkpoints of dueling dimers foil death wishes. Cell (1994) 3.45
bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development (1994) 3.34
Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci U S A (1994) 3.26
Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol (1993) 2.69
Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res (1994) 2.63
Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol (1994) 2.57
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem (1995) 2.35
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res (1991) 2.23
bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res (1992) 2.15
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res (1995) 1.98
Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol (1995) 1.97
Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res (1994) 1.89
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am (1995) 1.54
Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ (1995) 1.30
Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol (1988) 1.13
Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res (1995) 1.07
Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function. Cell Death Differ (1995) 1.07
BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med (1994) 1.07
Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer. Curr Opin Oncol (1994) 0.97
Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology (1995) 0.90
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Mitochondria and apoptosis. Science (1998) 23.41
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 11.26
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Mitochondrial control of cell death. Nat Med (2000) 9.17
X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 8.26
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 7.31
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 7.24
Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A (1998) 6.69
Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry (2008) 6.37
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol (1999) 6.24
Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res (1993) 5.83
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science (1998) 4.84
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science (1986) 4.79
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J (1997) 4.66
Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell (2001) 4.62
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell (1995) 4.53
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science (1999) 4.43
Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell (1994) 4.32
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell (1996) 4.04
Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature (1993) 4.00
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Anchorage dependence, integrins, and apoptosis. Cell (1994) 3.96
Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med (1999) 3.72
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J (1999) 3.51
Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci U S A (1997) 3.45
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest (1996) 3.42
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Caspase-9 can be activated without proteolytic processing. J Biol Chem (1999) 3.20
Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol (2000) 3.20
Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci U S A (1986) 3.19
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell (1998) 3.09
FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (1995) 3.06
Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res (1994) 3.02
Telepathology diagnosis of prostrate needle biopsies. Hum Pathol (1997) 2.99
An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem (1999) 2.97
Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med (2000) 2.96
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood (1993) 2.96
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem (1998) 2.93
BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J (1997) 2.91
The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci U S A (1995) 2.90
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ (2006) 2.85
The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med (1997) 2.83
Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem (1996) 2.79
Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol (2001) 2.68
BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem (2000) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem (1998) 2.64
Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res (1994) 2.63
Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem (2000) 2.62
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med (2000) 2.62
Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol (2001) 2.61
Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med (1997) 2.59
Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol (1994) 2.57
The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med (1998) 2.51
Integrin activation by R-ras. Cell (1996) 2.50
Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene (1994) 2.49
An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 2.47
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 2.45
p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol (2000) 2.42
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science (1987) 2.36
Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem (1995) 2.35
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development (1996) 2.35
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32